GlaxoSmithKline grants researchers access to clinical trial dataBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6909 (Published 12 October 2012) Cite this as: BMJ 2012;345:e6909
- Rebecca Coombes
GlaxoSmithKline has taken steps to open up more clinical data behind its drug trials, just months after the company was fined a record amount for ethical breaches.
From January all anonymised patient level data that sit hidden behind the results of clinical trials of its approved and failed drugs will be available without charge through a secure website once access has been approved.
Andrew Witty, GSK’s chief executive, said that the move sprang from a desire to dismiss the perception that drug companies are always “hiding something.”
“People have to really believe they are looking at the whole picture,” he …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial